Apr 28, 2025

Doseology Announces $1.2M Private Placement to Advance Commercialization

Kelowna, BC – April 28, 2025 – Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU7) (“Doseology” or the “Company”), an innovator in precision-formulated performance solutions, is pleased to announce a non-brokered private placement of up to 10,000,000 units (each a “Unit”) at $0.12 per Unit for gross proceeds of up to $1,200,000 (the “Private Placement”).

Each Unit consists of one common share (each a “Share”) and one common share purchase warrant (each a "Warrant"). Each Warrant is exercisable at $0.50 for a period of 24 months from the closing date of the Private Placement. If fully subscribed and all Warrants are exercised, this structure represents a potential capital inflow of $6.2 million.

This Private Placement replaces Doseology’s previously announced financing with a more strategically aligned structure—enhancing operational flexibility and positioning the Company to deliver greater long-term value to both existing and future shareholders.

Strategic Purpose

The capital will support the commercialization of Doseology's oral stimulant product line, which includes caffeine, nicotine, and other functional actives, delivered through innovative pouch systems. These clean, fast-acting formulations are designed to enhance energy, focus, and cognitive performance across North American and European markets. In parallel, the Company is actively engaging with industry veterans, operators, and experts across consumer health and wellness sectors to build a best-in-class execution team and accelerate market penetration.

"We're building a portfolio of category-defining assets in the oral stimulant space," said Chris Cherry, CFO of Doseology. "This structure is measured and performance-driven-aligning capital efficiency with our long-term strategy. It reflects our commitment to scaling both organically and through acquisition."

Use of Proceeds

Commercialization of Doseology's stimulant pouch product line
Expansion of distribution and retail across Canada, the U.S., and Europe
Engagement of top-tier industry talent
General working capital and brand development

Current Financial Position

As of this announcement, Doseology holds approximately $900,000 in cash on hand and carries no debt. The Private Placement is expected to significantly enhance the Company’s execution capacity as it advances toward commercial rollout.

Share Structure Snapshot

Issued and Outstanding: 4,500,515
Reserved for Issuance (options/warrants): 155,000
Units in this Private Placement (max): 10,000,000
Shares Post Closing (basic): 14,500,515
Warrants from this Private Placement: 10,000,000
Fully Diluted Total: 24,655,515

Warrant Acceleration

If Doseology's Shares trade at or above $0.75 for any 10 non-consecutive trading days after the four-month hold period, the Company may accelerate the expiry date of the Warrants with 30 days' notice.

Resale Restrictions

All securities issued in this Private Placement will be subject to the following escrow restrictions:

33% released after 4 months
33% released after 8 months
34% released after 12 months

Eligible Investors

This Private Placement is being conducted pursuant to exemptions under National Instrument 45-106 – Prospectus Exemptions. It is open to Canadian investors who qualify as:

Accredited Investors
Close personal friends or business associates of the Company’s officers or directors
Other eligible exempt purchasers in accordance with applicable securities laws

The Private Placement is subject to customary closing conditions, including approval by the Canadian Securities Exchange (CSE).

As the Private Placement exceeds 100% of the Company’s currently issued and outstanding common shares, shareholder approval is required under Section 4.6(2)(a)(i) of the CSE Policies. The Company intends to obtain this approval by written consent of shareholders in accordance with applicable requirements.

If you are interested in participating in this Private Placement, please contact hello@doseology.com.

About Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU7)

Doseology is a performance-driven innovation company at the intersection of biotechnology and advanced delivery systems, engineering precision-formulated oral stimulants that optimize energy, focus, and cognitive performance. Through science-backed research and cutting-edge formulation technologies, the Company is pioneering next-generation performance solutions that empower consumers to perform at their peak.

On behalf of the Board of Directors,
Chris Jackson
CEO
Doseology Sciences Inc.

For more information, please contact the Company at:
Email: hello@doseology.com
Website: www.doseology.com
Phone: 604.908.3095

Forward Looking Statements

This press release contains statements that constitute “forward‐looking information” within the meaning of applicable securities laws. Forward‐looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Company’s prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law. For more information, investors should review the Company’s filings which are available on SEDAR+.

No securities regulatory authority has either approved or disapproved of the contents of this press release. The Company’s securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration, or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.

Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.

Back to Investor News